Zanubrutinib 

MAFZanubrutinib Capsule 80 mg

1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
2) Monotherapy for patients with Waldenstrom’s macroglobulinemia (WM) who have received at least one prior therapy.
3) Monotherapy for previously untreated Waldenstrom’s macroglobulinemia (WM) in patients who are unsuitable for chemo-immunotherapy.
4) Monotherapy for relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen.
5) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
6) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.

MSHLZanubrutinib Capsule 80 mg

1) Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
2) Monotherapy for patients with Waldenstrom’s macroglobulinemia (WM) who have received at least one prior therapy.
3) Monotherapy for previously untreated Waldenstrom’s macroglobulinemia (WM) in patients who are unsuitable for chemo-immunotherapy.
4) Monotherapy for relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen.
5) Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy.
6) Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy.